Vontobel Holding Ltd. Trims Stake in DexCom, Inc. (NASDAQ:DXCM)

Vontobel Holding Ltd. reduced its holdings in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 50.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 35,024 shares of the medical device company's stock after selling 35,562 shares during the period. Vontobel Holding Ltd.'s holdings in DexCom were worth $2,724,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. Versant Capital Management Inc bought a new position in shares of DexCom during the 4th quarter worth about $25,000. Heck Capital Advisors LLC bought a new position in shares of DexCom during the 4th quarter worth about $38,000. RPg Family Wealth Advisory LLC bought a new position in shares of DexCom during the 3rd quarter worth about $57,000. Covestor Ltd boosted its position in shares of DexCom by 53.7% during the 3rd quarter. Covestor Ltd now owns 959 shares of the medical device company's stock worth $64,000 after purchasing an additional 335 shares in the last quarter. Finally, MassMutual Private Wealth & Trust FSB boosted its position in shares of DexCom by 46.7% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 833 shares of the medical device company's stock worth $65,000 after purchasing an additional 265 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at DexCom

In related news, COO Jacob Steven Leach sold 2,634 shares of DexCom stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $228,920.94. Following the completion of the transaction, the chief operating officer now directly owns 268,644 shares in the company, valued at approximately $23,347,850.04. The trade was a 0.97 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Jereme M. Sylvain sold 2,090 shares of DexCom stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $181,641.90. Following the completion of the transaction, the executive vice president now owns 83,526 shares of the company's stock, valued at $7,259,244.66. This represents a 2.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 38,083 shares of company stock worth $3,309,794 in the last quarter. Insiders own 0.30% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on DXCM shares. JPMorgan Chase & Co. increased their price objective on shares of DexCom from $75.00 to $85.00 and gave the stock a "neutral" rating in a research report on Friday, October 25th. Raymond James cut their price objective on shares of DexCom from $115.00 to $99.00 and set a "strong-buy" rating on the stock in a research report on Friday, October 25th. Oppenheimer dropped their price target on shares of DexCom from $115.00 to $105.00 and set an "outperform" rating on the stock in a research report on Friday, October 25th. Canaccord Genuity Group raised their price target on shares of DexCom from $99.00 to $103.00 and gave the company a "buy" rating in a research report on Friday, February 14th. Finally, Redburn Atlantic raised shares of DexCom from a "neutral" rating to a "buy" rating and raised their price target for the company from $85.00 to $115.00 in a research report on Monday, February 3rd. Four analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, DexCom presently has a consensus rating of "Moderate Buy" and a consensus target price of $99.06.

DexCom Stock Performance

Shares of DexCom stock traded down $0.85 during mid-day trading on Wednesday, hitting $89.68. 3,251,683 shares of the stock were exchanged, compared to its average volume of 3,638,701. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00. The company has a 50-day simple moving average of $83.06 and a 200 day simple moving average of $75.85. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. The company has a market capitalization of $35.03 billion, a P/E ratio of 62.71, a P/E/G ratio of 2.31 and a beta of 1.14.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. Sell-side analysts anticipate that DexCom, Inc. will post 1.98 earnings per share for the current fiscal year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.